294 related articles for article (PubMed ID: 1302044)
21. Evidence for the involvement of several cytochromes P-450 in the first steps of caffeine metabolism by human liver microsomes.
Berthou F; Flinois JP; Ratanasavanh D; Beaune P; Riche C; Guillouzo A
Drug Metab Dispos; 1991; 19(3):561-7. PubMed ID: 1680620
[TBL] [Abstract][Full Text] [Related]
22. Arachidonic acid metabolism by human cytochrome P450s 2C8, 2C9, 2E1, and 1A2: regioselective oxygenation and evidence for a role for CYP2C enzymes in arachidonic acid epoxygenation in human liver microsomes.
Rifkind AB; Lee C; Chang TK; Waxman DJ
Arch Biochem Biophys; 1995 Jul; 320(2):380-9. PubMed ID: 7625847
[TBL] [Abstract][Full Text] [Related]
23. Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2.
Labedzki A; Buters J; Jabrane W; Fuhr U
Biochem Pharmacol; 2002 Jun; 63(12):2159-67. PubMed ID: 12110375
[TBL] [Abstract][Full Text] [Related]
24. Analysis of within-subject variation of caffeine metabolism when used to determine cytochrome P4501A2 and N-acetyltransferase-2 activities.
McQuilkin SH; Nierenberg DW; Bresnick E
Cancer Epidemiol Biomarkers Prev; 1995 Mar; 4(2):139-46. PubMed ID: 7742721
[TBL] [Abstract][Full Text] [Related]
25. Paraxanthine/Caffeine Concentration Ratios in Hair: An Alternative for Plasma-Based Phenotyping of Cytochrome P450 1A2?
De Kesel PM; Lambert WE; Stove CP
Clin Pharmacokinet; 2015 Jul; 54(7):771-81. PubMed ID: 25603821
[TBL] [Abstract][Full Text] [Related]
26. Caffeine metabolism in liver slices during postnatal development in rats.
Bienvenu T; Pons G; Rey E; Thiroux G; Olive G
Drug Metab Dispos; 1993; 21(1):178-80. PubMed ID: 8095214
[TBL] [Abstract][Full Text] [Related]
27. The relative contribution of human cytochrome P450 isoforms to the four caffeine oxidation pathways: an in vitro comparative study with cDNA-expressed P450s including CYP2C isoforms.
Kot M; Daniel WA
Biochem Pharmacol; 2008 Aug; 76(4):543-51. PubMed ID: 18619574
[TBL] [Abstract][Full Text] [Related]
28. Theophylline has no advantages over caffeine as a putative model drug for assessing CYPIA2 activity in humans.
Rasmussen BB; Brøsen K
Br J Clin Pharmacol; 1997 Mar; 43(3):253-8. PubMed ID: 9088579
[TBL] [Abstract][Full Text] [Related]
29. Measurement of CYP1A2 activity: a focus on caffeine as a probe.
Perera V; Gross AS; McLachlan AJ
Curr Drug Metab; 2012 Jun; 13(5):667-78. PubMed ID: 22554278
[TBL] [Abstract][Full Text] [Related]
30. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites.
Butler MA; Lang NP; Young JF; Caporaso NE; Vineis P; Hayes RB; Teitel CH; Massengill JP; Lawsen MF; Kadlubar FF
Pharmacogenetics; 1992 Jun; 2(3):116-27. PubMed ID: 1306111
[TBL] [Abstract][Full Text] [Related]
31. Catabolic pathways and biotechnological applications of microbial caffeine degradation.
Dash SS; Gummadi SN
Biotechnol Lett; 2006 Dec; 28(24):1993-2002. PubMed ID: 17009088
[TBL] [Abstract][Full Text] [Related]
32. Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: coincidence with plasma clearance and breath test.
Rost KL; Roots I
Clin Pharmacol Ther; 1994 Apr; 55(4):402-11. PubMed ID: 8162667
[TBL] [Abstract][Full Text] [Related]
33. Caffeine and theophylline metabolism in newborn and adult human hepatocytes; comparison with adult rat hepatocytes.
Berthou F; Ratanasavanh D; Alix D; Carlhant D; Riche C; Guillouzo A
Biochem Pharmacol; 1988 Oct; 37(19):3691-700. PubMed ID: 3178881
[TBL] [Abstract][Full Text] [Related]
34. Oxidation of caffeine to theobromine and theophylline is catalyzed primarily by flavin-containing monooxygenase in liver microsomes.
Chung WG; Cha YN
Biochem Biophys Res Commun; 1997 Jun; 235(3):685-8. PubMed ID: 9207220
[TBL] [Abstract][Full Text] [Related]
35. The use of caffeine for enzyme assays: a critical appraisal.
Kalow W; Tang BK
Clin Pharmacol Ther; 1993 May; 53(5):503-14. PubMed ID: 8491061
[No Abstract] [Full Text] [Related]
36. [Evaluation of pharmacokinetic interaction of aphobazole with CYP1A2 drug-substrate in experiments].
Novitskaia IaG; Litvin AA; Viglinskaia AO; Zherdev VP
Eksp Klin Farmakol; 2013; 76(6):30-3. PubMed ID: 24003488
[TBL] [Abstract][Full Text] [Related]
37. Human disposition and some biochemical aspects of methylxanthines.
Yesair DW; Branfman AR; Callahan MM
Prog Clin Biol Res; 1984; 158():215-33. PubMed ID: 6396646
[TBL] [Abstract][Full Text] [Related]
38. Caffeine as a probe for CYP1A2 activity: potential influence of renal factors on urinary phenotypic trait measurements.
Tang BK; Zhou Y; Kadar D; Kalow W
Pharmacogenetics; 1994 Jun; 4(3):117-24. PubMed ID: 7920691
[TBL] [Abstract][Full Text] [Related]
39. Caffeine metabolites in umbilical cord blood, cytochrome P-450 1A2 activity, and intrauterine growth restriction.
Grosso LM; Triche EW; Belanger K; Benowitz NL; Holford TR; Bracken MB
Am J Epidemiol; 2006 Jun; 163(11):1035-41. PubMed ID: 16641310
[TBL] [Abstract][Full Text] [Related]
40. Interindividual variation in relative CYP1A2/3A4 phenotype influences susceptibility of clozapine oxidation to cytochrome P450-specific inhibition in human hepatic microsomes.
Zhang WV; D'Esposito F; Edwards RJ; Ramzan I; Murray M
Drug Metab Dispos; 2008 Dec; 36(12):2547-55. PubMed ID: 18809730
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
